NCT00983814 - Study of Droxidopa Treatment in Adults With Attention Deficit Hyperactivity Disorder With Co-administration of Carbidopa | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

May 31, 2011

Study Completion Date

July 31, 2011

Conditions

Attention Deficit Hyperactivity Disorder

Interventions

DRUG

Droxidopa+Carbidopa

3 weeks of open label droxidopa (L-dihydroxyphenylserine (L-DOPS)) (200, 400, or 600mgs TID) monotherapy followed by 3 weeks of droxidopa in combination with carbidopa (25mg or 50mg TID) followed by 2 weeks of double blind continued droxidopa+carbidopa or placebo

Trial Locations (1)

10010

VA New York Harbor Healthcare System/New York University Langone Medical Center, New York